Clinical Trial Update: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial comparing chemotherapy versus letrozole plus abemaciclib in HR+/HER2- high/intermediate risk early breast cancer; status is ACTIVE_NOT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Early Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-12